GE Healthcare’s Life Sciences business has sealed the deal for the exclusive rights from Rapiscan Pharma Solutions to commercialize Rapiscan (Regadenoson), used in the diagnosis of coronary artery disease (CAD), in territories outside the U.S., Canada and Mexico.